Drug Profile
Research programme: oral influenza vaccine - Creato Flu
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Creato Flu
- Class Influenza virus vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Influenza virus infections
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Influenza-virus-infections in Germany (PO)
- 27 Jun 2009 Creato Flu seeks partnerships for the research project and further clinical development of oral vaccine (http://creatogen.de)
- 27 Jun 2009 Preclinical trials in Influenza virus infections in Germany (PO)